Scilex Holding Company (SCLX)Healthcare | Drug Manufacturers - General | Palo Alto, United States | NasdaqCM
6.85 USD
-0.10
(-1.368%) ⇩
(April 21, 2026, 12:29 p.m.
EDT)
Short-term: ★★☆☆☆ | Long-term: ★☆☆☆☆ | Dividends: ★★☆☆☆ |
Hot Take | April 19, 2026, 12:12 a.m. EDT
Scilex Holding Company presents a severe long-term trap due to collapsing fundamentals (-68% revenue growth, negative operating margins, and negative book value), while short-term momentum remains oversold with a sharp 26% drop; however, the anticipated blip in recent price action is insufficient to overcome the structural decline. |
| Model | MAE |
|---|---|
| AutoTheta ✓ | 0.135310 |
| AutoARIMA | 0.294149 |
| AutoETS | 0.294154 |
| MSTL | 0.306757 |
Forecast horizon: 45 days | Selected: AutoTheta
| Forecast Reliability | |
|---|---|
| Score | 71% |
| H-stat | 1.29 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.532 |
| Excess Kurtosis | 0.10 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Revenue per Share | 2.742 |
| Market Cap | 48,176,084 |
| Forward P/E | 9.38 |
| Beta | 1.42 |
| Website | https://www.scilexholding.com |
| Attribute | Value |
|---|---|
| 52 Week Change | 0.74060154 |
| Address1 | 960 San Antonio Road |
| All Time High | 591.5 |
| All Time Low | 3.6 |
| Ask | 6.69 |
| Ask Size | 1 |
| Average Daily Volume10 Day | 61,710 |
| Average Daily Volume3 Month | 47,577 |
| Average Volume | 47,577 |
| Average Volume10Days | 61,710 |
| Beta | 1.415 |
| Bid | 5.55 |
| Bid Size | 1 |
| Book Value | -29.544 |
| City | Palo Alto |
| Compensation As Of Epoch Date | 1,735,603,200 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 6.85 |
| Current Ratio | 0.079 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,774,915,200 |
| Day High | 7.1551 |
| Day Low | 6.765 |
| Display Name | Scilex Holding |
| Earnings Timestamp End | 1,773,349,200 |
| Earnings Timestamp Start | 1,773,349,200 |
| Ebitda | -267,680,992 |
| Ebitda Margins | 0.0 |
| Enterprise To Ebitda | -0.622 |
| Enterprise To Revenue | 5.501 |
| Enterprise Value | 166,436,208 |
| Eps Current Year | -0.89 |
| Eps Forward | 0.73 |
| Eps Trailing Twelve Months | -36.48 |
| Esg Populated | 0 |
| Exchange | NCM |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 7.697 |
| Fifty Day Average Change | -0.8470001 |
| Fifty Day Average Change Percent | -0.11004289 |
| Fifty Two Week Change Percent | 74.06015 |
| Fifty Two Week High | 34.27 |
| Fifty Two Week High Change | -27.42 |
| Fifty Two Week High Change Percent | -0.8001167 |
| Fifty Two Week Low | 3.6 |
| Fifty Two Week Low Change | 3.25 |
| Fifty Two Week Low Change Percent | 0.9027778 |
| Fifty Two Week Range | 3.6 - 34.27 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,614,954,600,000 |
| Float Shares | 4,709,862 |
| Forward Eps | 0.73 |
| Forward P E | 9.383561 |
| Free Cashflow | 24,583,124 |
| Full Exchange Name | NasdaqCM |
| Full Time Employees | 34 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Gross Margins | 0.64965 |
| Gross Profits | 19,654,000 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.17557 |
| Held Percent Institutions | 0.13477 |
| Implied Shares Outstanding | 7,033,005 |
| Industry | Drug Manufacturers - General |
| Industry Disp | Drug Manufacturers - General |
| Industry Key | drug-manufacturers-general |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Last Split Date | 1,744,675,200 |
| Last Split Factor | 1:35 |
| Long Business Summary | Scilex Holding Company focuses on acquiring, developing, and commercializing non-opioid pain management products for the treatment of acute and chronic pain. Its commercial products include ZTlido (lidocaine topical system) 1.8% (ZTlido), a prescription lidocaine topical product for the relief of neuropathic pain associated with postherpetic neuralgia (PHN), which is a form of post-shingles nerve pain; ELYXYB, a ready-to-use oral solution for the acute treatment of migraine with or without aura in adults; and GLOPERBA, a liquid oral version of the anti-gout medicine colchicine indicated for the prophylaxis of painful gout flares in adults. The company also develops three product candidates, including SP-102 (10 mg, dexamethasone sodium phosphate viscous gel - SEMDEXA), a novel viscous gel formulation of a used corticosteroid for epidural injections, which has completed a phase 3 study to treat lumbosacral radicular pain or sciatica; SP-103 (lidocaine topical system) 5.4%, a formulation of ZTlido for the treatment of chronic neck pain and low back pain (LBP) that has completed a phase 2 trial; and SP-104 (4.5 mg low-dose naltrexone hydrochloride delayed-release capsules), a novel low-dose delayed-release naltrexone hydrochloride, which has completed phase 1 trials for the treatment of fibromyalgia. It has an agreement with Oishi and Itochu to develop lidocaine tape products, including ZTlido and SP-103; and Lifecore Biomedical, LLC for clinical trial material manufacturing and development services for SEMDEXA. Scilex Holding Company is based in Palo Alto, California. |
| Long Name | Scilex Holding Company |
| Market | us_market |
| Market Cap | 48,176,084 |
| Market State | REGULAR |
| Max Age | 86,400 |
| Message Board Id | finmb_607715156 |
| Most Recent Quarter | 1,767,139,200 |
| Net Income To Common | -402,487,008 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 48,844,212 |
| Open | 6.95 |
| Operating Cashflow | 3,816,000 |
| Operating Margins | -7.8201504 |
| Payout Ratio | 0.0 |
| Phone | 650 516 4310 |
| Previous Close | 6.945 |
| Price Eps Current Year | -7.696629 |
| Price Hint | 2 |
| Price To Book | -0.23185755 |
| Price To Sales Trailing12 Months | 1.5924399 |
| Profit Margins | 0.0 |
| Quick Ratio | 0.054 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | none |
| Region | US |
| Regular Market Change | -0.09500027 |
| Regular Market Change Percent | -1.3678944 |
| Regular Market Day High | 7.1551 |
| Regular Market Day Low | 6.765 |
| Regular Market Day Range | 6.765 - 7.1551 |
| Regular Market Open | 6.95 |
| Regular Market Previous Close | 6.945 |
| Regular Market Price | 6.85 |
| Regular Market Time | 1,776,788,985 |
| Regular Market Volume | 18,930 |
| Return On Assets | -0.74329 |
| Revenue Growth | -0.678 |
| Revenue Per Share | 2.742 |
| Sand P52 Week Change | 0.34445214 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Shares Outstanding | 7,033,004 |
| Shares Percent Shares Out | 0.026700001 |
| Shares Short | 187,953 |
| Shares Short Previous Month Date | 1,772,150,400 |
| Shares Short Prior Month | 219,332 |
| Short Name | Scilex Holding Company |
| Short Percent Of Float | 0.0339 |
| Short Ratio | 5.78 |
| Source Interval | 15 |
| State | CA |
| Symbol | SCLX |
| Total Cash | 10,981,000 |
| Total Cash Per Share | 1.561 |
| Total Debt | 132,543,000 |
| Total Revenue | 30,253,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -36.48 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 13.998325 |
| Two Hundred Day Average Change | -7.1483254 |
| Two Hundred Day Average Change Percent | -0.51065576 |
| Type Disp | Equity |
| Volume | 18,930 |
| Website | https://www.scilexholding.com |
| Zip | 94,303 |